3rd Workshop European Network on Viral Vaccine Processes

Programme

Monday, November 25, 2013
  VACCINE DESIGN
09.00 h lNVITED LECTURE

Emerging viruses: a veterinary view at challenges of control at the interfaces of wildlife-livestock-humans

  T. Harder, Friedrich-Loeffler-Institut, Greifswald-Insel Riems/D
09.30 h

INVITED LECTURE
Development and production of nonspreading Rift Valley fever vaccines

  R. Moormann, Wageningen University, Lelystad and Utrecht University/NL; N. Ohreshkova, J. Kortekaas, Wageningen, Lelystad/NL
10.00 h

INVITED LECTURE
Modified vaccinia virus Ankara vectors for antigen delivery - from (pre)clinical evaluation to process development

  G. Sutter, University of Munich/D
10.30 h New approaches for designing, control and manufacturing viral vaccines
  C. Pereira, Instituto Butantan, São Paulo/BR
10.50 h A platform to determine the impact of influenza virus hemagglutinin N-glycosylation on immunogenicity
  J. Hütter, MPI of Colloids and Interfaces, Potsdam/D; J.V. Rödig, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; D. Höper, Friedrich-Loeffler-Institut, Greifswald - Insel Riems/D; P.H. Seeberger, MPI of Colloids and Interfaces, Potsdam/D; U. Reichl, MPI for Dynamics of Complex Technical Systems and University of Magdeburg/D; E. Rapp, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; B. Lepenies, MPI of Colloids and Interfaces, Potsdam/D
11.10 h Coffee Break
  CELL SUBSTRATES AND ENGINEERING
11.30 h Single step cloning-titration method: enabling tools for virus producer cell line development and engineering
  A.F. Rodrigues, A.S. Oliveira, M.R. Guerreiro, H. Tomas, M.J.T. Carrondo, P.M. Alves, A.S. Coroadinha, IBET - Instituto de Biologia Experimental e Tecnológica, Oeiras/P
11.50 h Adaptation of a vaccine virus to production in suspension cultures
  I. Jordan, V. Sandig, ProBioGen AG, Berlin/D
12.10 h Human CAP cells as novel platform for production of vaccines
  G. Schiedner, CEVEC Pharmaceuticals GmbH, Cologne/D
12.30 h Capturing cell's quality: how to measure the infectability of PER.C6® cells by viruses?
  S.M. Mercier, B. Diepenbroek, Crucell, Leiden/NL; R.H. Wijffels, M. Streefland, Wageningen University/NL
13.00 h Lunch Break
  BIOREACTION / UPSTREAM
14.00 h INVITED LECTURE

Towards large scale AAV vector production: process development, bottlenecks, and perspectives

  O.-W. Merten, Généthon, Evry Cedex/F
14.30 h INVITED LECTURE
Manufacturing of AAV gene-therapy products
  A. van Oorschot, uniQure, Amsterdam/NL
15.00 h Viral vector production in the integrityTM iCELLis® disposable fixed-bed bioreactor from bench-scale to industrial scale
  A. Lennaertz, S. Knowles, J.C. Drugmand, J. Castillo, ATMI LifeSciences, Brussels/B
15.20 h Continuous cell culture-based influenza vaccine production
  T. Frensing, S. Heldt, I. Behrendt, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; I. Jordan, ProBioGen AG, Berlin/D; Y. Genzel, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; U. Reichl, MPI for Dynamics of Complex Technical Systems and University of Magdeburg/D
15.20 h Scale-down of the inactivated polio vaccine production process
  Y.E. Thomassen, A.G. van't Oever, M. Vinke, A. Spiekstra, L.A. van der Pol, W.A.M. Bakker, Institute for Translational Vaccinology, Bilthoven/NL
16.00 h Coffee Break
  ONCOLYTIC VIRUSES
16.15 h INVITED LECTURE
Viral gene transfer vectors: regulatory aspects and innovations in surface targeting
  C.J. Buchholz, Paul-Ehrlich-Institut, Langen/D
16.45 h INVITED LECTURE
Oncolytic virus production and purification challenges for human clinical trials: case study measles virus
  M. Federspiel, Mayo Clinic, Rochester, MN/USA
17.15 h - 18.15 h POSTER SESSION
P.01 From bench scale to industrial scale: using the integrityTM iCELLis® disposable fixed-bed bioreactor to scale-up production of viral entities
  J.C. Drugmand, S. Knowles, N. Vertommen, J. Castillo, F. Debras, ATMI LifeSciences, Brussels/B
P.02 Improving adenovirus purification by using enhanced membrane chromatography
  P. Nestola, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; L. Villain, Sartorius Stedim Biotech, Gottingen/D; C. Peixoto, P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; J.P.B. Mota, Requimte/CQFB, FCT/UNL, Caparica/P; M.J.T. Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P
P.03 Improving viral vaccine production by interfering in the viral life cycle and by identifying new producer cell lines
  D. Oosterhoff, L. van der Pol, W.A. Bakker, Intravacc, Bilthoven/NL
P.04 Development of an industrial platform for the production of rAAV
  A. Pegel, J. Wegele, M. Kunz, C. Küppers, A. Schulze, A. Rößner, D. Kreß, F. Sonntag, M. Hörer, Rentschler Biotechnologie GmbH, Laupheim/D
P.05 Novel tools could give stable producer cell lines their break for commercial manufacturing of recombinant AAV vectors
  V. Emmerling, Rentschler Biotechnologie GmbH, Laupheim/D and Ulm University/D; K. Holzmann, K. Lanz, Ulm University/D; J. Wegele, Rentschler Biotechnologie GmbH, Laupheim/D; S. Kochanek, Ulm University/D; M. Hörer, Rentschler Biotechnologie GmbH, Laupheim/D
P.06 Human amniocyte-derived cells for production of adenovirus vectors for gene therapy
  A.C. Silva, IBET- Instituto de Biologia Experimental e Tecnológica and ITQB-UNL, Oeiras/P; D. Simão, M.F.Q. Sousa, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; C. Küppers, T. Lucas, Ulm University, Ulm/D; P.E. Cruz, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; M.J.T. Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica and ITQB-UNL, Oeiras/P; S. Kochanek, Ulm University, Ulm/D; P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica and ITQB-UNL, Oeiras/P
P.07 Chikungunya virus-like particle vaccine produced in insect cells
  S.W. Metz, J. Gardner, C. Geertsema, TT. Le, L. Goh, J.M. Vlak, A. Suhrbier, G.P. Pijlman, Wageningen University/NL
19:00 h
Social Event
   

 

Tuesday, November 26, 2013
  PURIFICATION / DOWNSTREAM / PROCESS CONTROL
09.00 h Emerging new tools for improving downstream processing for viral vaccine and viral vectors
  P. Nestola, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; L. Villain, Sartorius Stedim Biotech, Gottingen/D; C. Peixoto, P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; J.P.B Mota, Requimte/CQFB, Departamento de Química, FCT/UNL, Caparica/P; M.J.T Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P
09.20 h Can membrane chromatography streamline influenza virus purification?
  A. Cvetkovic, R. Gantier, Pall Corporation, Westborough, MA/USA; A. Onraedt, Pall International, Fribourg/CH
09.40 h Purification of Enterovirus 71 like particles for vaccine production by the use of different membrane adsorbers
  M. Meininger, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; R. Djurup, Rebidu, Gentofte/DK; L. Villain, Sartorius-Stedim Biotech GmbH, Göttingen/D; J. Cardosa, Sentinext Therapeutics Sdn Bhd, Penang/MAL; U. Reichl, M. Wolff, MPI for Dynamics of Complex Technical Systems, Magdeburg/D
10.00 h Ultrafiltration membranes in downstream processing for vaccine production
  T. Schleuss, H.-H. Hörl, U. Grummert, Sartorius Stedim Biotech GmbH, Göttingen/D; C. Peixoto, D. Martins, IBET, Oeiras/P
10.20 h High-throughput process development for the purification of virus-like particles
  C. Ladd Effio, L. Wenger, S.A. Oelmeier, J. Hubbuch, Karlsruhe Institute of Technology (KIT)/D
10.40 h Coffee Break
11.00 h Introduction of PAT to improve the efficiency and robustness of vaccine development and manufacturing
  A. Strancar, BIA Separations, Ajdovscina/SLO
11.20 h Best practices in nucleic acid removal from vaccine processes
  F. Appel, Merck Millipore, Darmstadt/D
11:40 h
Scale-up study: single use bioprocessing for influenza virus
  J. Royce, GE Healthcare Life Sciences, Uppsala/S
12.00 h Purification of cell culture-derived influenza virus via continuous size exclusion chromatography
  T. Kröber, L.M. Fischer, M.W. Wolff, U. Reichl, MPI for Dynamics of Complex Technical Systems, Magdeburg/D
12:20 h - 13:00 h
Wrap-up discussion

 

Download Programme as pdf-file.

Jetzt Mitglied werden